Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479 shares, an increase of 26.1% from the November 30th total of 399,288 shares. Currently, 10.8% of the shares of the company are sold short. Based on an average daily trading volume, of 145,440 shares, the short-interest ratio is currently 3.5 days. Based on an average daily trading volume, of 145,440 shares, the short-interest ratio is currently 3.5 days. Currently, 10.8% of the shares of the company are sold short.Get Kalaris Therapeutics alerts:Analysts Set New Price TargetsSeveral research firms recently issued reports on KLRS. Citizens Jmp began coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a "market outperform" rating and a $20.00 target price on the stock. Raymond James Financial began coverage on Kalaris Therapeutics in a report on Tuesday, September 2nd. They issued a "strong-buy" rating on the stock. Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, December 20th. Chardan Capital started coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a "buy" rating and a $19.00 target price on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kalaris Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kalaris Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $14.00.Read Our Latest Research Report on Kalaris TherapeuticsInstitutional Investors Weigh In On Kalaris TherapeuticsSeveral hedge funds have recently modified their holdings of the company. Woodline Partners LP acquired a new position in Kalaris Therapeutics in the 3rd quarter worth about $1,394,000. Belpointe Asset Management LLC acquired a new stake in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics in the third quarter valued at approximately $231,000. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics during the 2nd quarter worth approximately $65,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $130,000. 66.05% of the stock is owned by hedge funds and other institutional investors. Kalaris Therapeutics Stock Down 8.2%Kalaris Therapeutics stock opened at $8.38 on Wednesday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The firm has a market cap of $156.71 million, a price-to-earnings ratio of -2.22 and a beta of -0.04. The business's 50-day moving average price is $6.63 and its 200 day moving average price is $4.67. Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.02. Kalaris Therapeutics Company Profile (Get Free Report)Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.Read MoreFive stocks we like better than Kalaris TherapeuticsDo not delete, read immediatelyThe Crash Has Already Started (Most Just Don’t See It Yet)ALERT: Drop these 5 stocks before January 2026![No Brainer Gold Play]: “Show me a better investment.”INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Kalaris Therapeutics Right Now?Before you consider Kalaris Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kalaris Therapeutics wasn't on the list.While Kalaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here